TheraRadar
Data updated: May 26, 2026

XERAVA (eravacycline dihydrochloride)

Priority Review Fast Track
Infectious Disease Approved 2018-08-27

XERAVA is indicated for the treatment of Intra-abdominal Infections.

Source: FDA Label • TETRAPHASE PHARMS

How XERAVA Works

Eravacycline is a synthetic fluorocycline antibacterial within the tetracycline class. It exerts its bacteriostatic effect by binding to the 30S ribosomal subunit, which prevents the binding of aminoacyl-tRNA to the A-site of the ribosome. This action inhibits bacterial protein synthesis and the incorporation of amino acid residues into elongating peptide chains. Eravacycline is designed to retain activity against bacteria expressing common tetracycline resistance mechanisms, such as efflux pumps and ribosomal protection proteins.

1
Indication
--
Phase 3 Trials
1
Priority Reviews
7
Years on Market

Details

Status
Prescription
First Approved
2018-08-27
Patent Cliff
2037

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAVENOUS
Dosage Forms
POWDER

Companies

Active Ingredient: ERAVACYCLINE DIHYDROCHLORIDE

XERAVA Approval History

2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
10 FDA actions from 2018 to 2025
Mar 2025 SUPPL
Label · Labeling
Dec 2024 SUPPL
Label · Labeling
Jun 2020 SUPPL
Mfg · Manufacturing (CMC)

What XERAVA Treats

1 indications

XERAVA is approved for 1 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Intra-abdominal Infections
Source: FDA Label

XERAVA Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to XERAVA

3 of 11

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMPICILLIN AND SULBACTAM
AMPICILLIN SODIUM
1 shared
ISTITUTO BIO ITA SPA
Shared indications:
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
CEFEPIME HYDROCHLORIDE
1 shared
B BRAUN
Shared indications:
ERTAPENEM SODIUM
ERTAPENEM SODIUM
1 shared
SAVIOR LIFETEC CORP
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XERAVA FDA Label Details

Indications & Usage

FDA Label (PDF)

XERAVA is indicated for the treatment of Intra-abdominal Infections.

View full patent landscape →
4 OB patents · 2 families · 132 international docs across 34 countries

XERAVA Patents & Exclusivity

Latest Patent: Oct 2037
Exclusivity: Aug 2028

Patents (4 active)

US11578044 Expires Oct 19, 2037
US10961190 Expires Oct 19, 2037
US8906887 Expires Aug 27, 2032
US8796245 Expires Aug 7, 2029

Exclusivity

NCE Until Aug 2023
NCE Until Aug 2023
GAIN Until Aug 2028
GAIN Until Aug 2028
NCE Until Aug 2023
NCE Until Aug 2023
GAIN Until Aug 2028
GAIN Until Aug 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for XERAVA

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2037
  • 16 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 11 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.